AI assistant
Cellectar Biosciences, Inc. — Director's Dealing 2014
Sep 10, 2014
35021_dirs_2014-09-10_3df91a3f-f5a7-4521-a13f-b4f46aa45b28.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2014-09-08
Reporting Person: MARXE AUSTIN W & GREENHOUSE DAVID M (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-09-08 | Common Stock | P | 182 | $3 | Acquired | 1142368 | Indirect |
Footnotes
F1: This is a joint filing by Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner). They share voting and investment control over all securities owned by Special Situations Fund III QP, L.P. (QP), Special Situations Cayman Fund, L.P. (Cayman), and Special Situations Life Sciences Fund, L.P. (LS), respectively. 539,418 shares of Common Stock are held by QP, 179,806 shares of Common Stock are held by Cayman and 423,144 shares of Common Stock are held by LS. The interest of Marxe, Greenhouse and Stettner in the shares of Common Stock owned by QP, Cayman and LS is limited to the extent of his pecuniary interest.